Bright Minds is a biotechnology company developing next generation therapeutics for patients with severe and life-threatening brain diseases. They have a broad portfolio of new chemical entities to treat neuropsychiatric disorders as well as pain indications and seizures. They have compounds in late -pre clinical stage trials for the treatment of opioid use disorder, binge eating disorder and Alzheimer’s and early pre-clinical trials for the treatment of depression and PTSD.